PacBio and TychoBio Partner to Advance RNA Therapy Research

PacBio, a developer of advanced sequencing technologies, has partnered with TychoBio, an AI drug discovery company. The collaboration aims to generate full-length RNA data that TychoBio will use to train models for RNA therapy design. Under the agreement, the companies plan to gather data from over 10,000 samples, focusing on steric blocking antisense oligonucleotides (SBOs) and other RNA-targeting compounds.

The partnership involves using PacBio's Kinnex long-read RNA sequencing and HiFi sequencing to characterize how various candidate therapies change the transcriptome across multiple cell types. This detailed information is intended to accelerate the development of models that predict efficacy and potential side effects of new compounds.